Questcor's looming Medicaid rebate liability

Later this year, Questcor will be hit by a wave of new Medicaid rebate claims on its pricey drug Acthar as managed-care plans take advantage of a rebate provision tucked into the federal healthcare law. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.